Kleyn C Elise, Griffiths Christopher E M
The Dermatology Centre, Hope Hospital, The University of Manchester, Salford, Manchester, M6 8HD, UK.
Expert Opin Biol Ther. 2006 Aug;6(8):797-805. doi: 10.1517/14712598.6.8.797.
Psoriasis is a common immune-mediated skin disease producing significant morbidity. Tumour necrosis factor (TNF)-alpha, a pro-inflammatory cytokine, plays a key role in the cutaneous inflammation characteristic of psoriasis. Infliximab is a chimeric monoclonal antibody that specifically binds to TNF-alpha, thereby blocking its biological activity. Data from Phase II and III studies indicate that infliximab is a highly effective, rapidly acting systemic therapy for patients with moderate-to-severe psoriasis. Regular 8-weekly infusions of infliximab maintain significant clinical improvement in the majority of patients for at least 1 year. Infliximab is generally well tolerated, but patients may be susceptible to infection and malignancy.
银屑病是一种常见的免疫介导性皮肤病，会导致严重的发病率。肿瘤坏死因子（TNF）-α是一种促炎细胞因子，在银屑病的皮肤炎症特征中起关键作用。英夫利昔单抗是一种嵌合单克隆抗体，它能特异性结合TNF-α，从而阻断其生物活性。II期和III期研究数据表明，英夫利昔单抗对中重度银屑病患者是一种高效、速效的全身治疗方法。每8周定期输注英夫利昔单抗可使大多数患者保持显著的临床改善至少1年。英夫利昔单抗总体耐受性良好，但患者可能易发生感染和恶性肿瘤。
